Dr. Devarat Arya

MBBS, MD (Internal Medicine), DM (Medical Oncology)

Senior Director – Department of Medical Oncology

18+ Years of Experience
Delhi NCR

Dr. Devarat Arya is an exceptionally brilliant, highly respected senior leader in the modern generation of Medical Oncologists in South Asia. Holding a premier super-specialty DM in Medical Oncology, Dr. Arya represents the peak tier of evidence-based cancer therapeutics and personalized oncology. He is widely sought after by international and domestic patients for his meticulous attention to micro-clinical detail and his reassuringly calm, articulate approach. He specializes in formulating highly advanced chemotherapy lines, precision target-oriented biological therapies, and cutting-edge cancer immunotherapies. His patient-first communication strategy ensures that families feel thoroughly secure and confident before beginning intensive systemic cancer care protocols.

  • Solid Tumor Therapeutics: Advanced medical protocols and biological targeted lines for breast cancers, lung malignancies, colorectal tumors, and ovarian cancers.

  • Precision Cancer Immunotherapy: Deploying modern checkpoint inhibitors and targeted immune therapies to aggressively dismantle treatment-resistant malignancies.

  • Hematological Oncology Management: Formulating comprehensive targeted chemotherapy lines to treat adult leukemias, multiple myelomas, and lymphomas.

  • Targeted Cellular Interventions: Utilizing advanced genetic and molecular profiling of tumors to deliver customized, precision medication tracks.
  • Successfully guided thousands of cancer warriors through complex, intense curative systemic therapeutic journeys with an exceptional track record of clinical safety and success.

  • Actively contributed to establishing state-of-the-art multi-disciplinary tumor board workflows matching global oncology safety protocols at Max Hospital.

  • Published extensive research inside indexed international medical journals focusing on minimizing systemic toxicities in patients undergoing concurrent chemo-radiation tracks.
  • Awarded multiple academic gold medals and young investigator fellowships during his advanced super-specialty milestones.

  • Active senior member of the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO).